Federica Di Nicolantonio

Alıntı yapanlar

	Hepsi	2019 yılından bugüne
Alıntılar	28703	13466
h-endeksi	61	54
i10-endeksi	125	103

2600

1300

650

1950

2005200620072008200920102011201220132014201520162017201820192020202120222023202488 145 204 299 488 831 882 1052 1292 1609 1819 1980 2079 2099 2268 2373 2577 2271 2134 1830

Genel erişim

Tümünü görüntüle

99 makale

3 makale

genel erişime açık olanlar

genel erişime açık olmayanlar

Finansman sağlayan kuruluşun getirdiği zorunluluğa dayalı olarak

Katkıda bulunan yazarlar

Salvatore SienaUniversità degli Studi di Milano, Dipartimento di Oncologia, Ospedale Niguarda, Milano, Italyunimi.it üzerinde doğrulanmış e-posta adresine sahip
Andrea Sartore-BianchiClinical Molecular Oncology, Niguarda Cancer Center, Milano - Italyospedaleniguarda.it üzerinde doğrulanmış e-posta adresine sahip
Sabrina ArenaIRCC-University of Torino Medical School Laboratory of Molecular Genetics S.P. 142, km 3.95 Candioloircc.it üzerinde doğrulanmış e-posta adresine sahip
Livio TrusolinoProfessor, University of Torino School of Medicine, Italyircc.it üzerinde doğrulanmış e-posta adresine sahip
Andrea BertottiUniversity of Torino - School of Medicineircc.it üzerinde doğrulanmış e-posta adresine sahip
Miriam MartiniPhD, Università degli Studi di Torinounito.it üzerinde doğrulanmış e-posta adresine sahip
Ian CreeHead of WHO Classification of Tumours, IARC, Lyon, Franceiarc.fr üzerinde doğrulanmış e-posta adresine sahip
Sandra MisaleAssistant Professor of Oncology, Johns Hopkins University School of Medicinemskcc.org üzerinde doğrulanmış e-posta adresine sahip
Alessio AmatuNiguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italyospedaleniguarda.it üzerinde doğrulanmış e-posta adresine sahip
Enzo MedicoProfessor of Histology, University of Torino and Head of the Laboratory of Oncogenomics, Candioloircc.it üzerinde doğrulanmış e-posta adresine sahip
Rene BernardsNetherlands Cancer Institutenki.nl üzerinde doğrulanmış e-posta adresine sahip
Chong SunGerman Cancer Research Center (DKFZ)dkfz.de üzerinde doğrulanmış e-posta adresine sahip
Federico BussolinoFull Professor of Biochemistry. Department of Oncology. University of Torino-Italyunito.it üzerinde doğrulanmış e-posta adresine sahip
Sidong HuangMcGill Universitymcgill.ca üzerinde doğrulanmış e-posta adresine sahip
Manel EstellerDirector, Josep Carreras Leukaemia Research Institute. University of Barcelona and ICREAcarrerasresearch.org üzerinde doğrulanmış e-posta adresine sahip

Takip et

Federica Di Nicolantonio

University of Torino, Dept of Oncology & Candiolo Cancer Institute, FPO - IRCCS

unito.it üzerinde doğrulanmış e-posta adresine sahip - Ana Sayfa

Liquid Biopsy Colorectal cancer Cancer Epigenetics Biomarkers Molecular diagnostics


Başlık Alıntılara göre sırala Yıla göre sırala Başlığa göre sırala	Alıntı yapanlar Alıntı yapanlar	Yıl
Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR A Prahallad, C Sun, S Huang, F Di Nicolantonio, R Salazar, D Zecchin, ... Nature 483 (7387), 100-103, 2012	2234	2012
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer F Di Nicolantonio, M Martini, F Molinari, A Sartore-Bianchi, S Arena, ... Journal of clinical oncology 26 (35), 5705-5712, 2008	2189	2008
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ... Nature 486 (7404), 532-536, 2012	2081	2012
Liquid biopsy: monitoring cancer-genetics in the blood E Crowley, F Di Nicolantonio, F Loupakis, A Bardelli Nature reviews Clinical oncology 10 (8), 472-484, 2013	2018	2013
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study M Moroni, S Veronese, S Benvenuti, G Marrapese, A Sartore-Bianchi, ... The lancet oncology 6 (5), 279-286, 2005	1178	2005
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ... Nature medicine 21 (7), 795-801, 2015	1146	2015
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti–epidermal growth factor receptor antibody therapies S Benvenuti, A Sartore-Bianchi, F Di Nicolantonio, C Zanon, M Moroni, ... Cancer research 67 (6), 2643-2648, 2007	1092	2007
A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corà, ... Cancer discovery 1 (6), 508-523, 2011	1041	2011
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies A Sartore-Bianchi, M Martini, F Molinari, S Veronese, M Nichelatti, ... Cancer research 69 (5), 1851-1857, 2009	938	2009
Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma C Sun, L Wang, S Huang, GJJE Heynen, A Prahallad, C Robert, ... Nature 508 (7494), 118-122, 2014	922	2014
Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab W De Roock, DJ Jonker, F Di Nicolantonio, A Sartore-Bianchi, D Tu, ... Jama 304 (16), 1812-1820, 2010	894	2010
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ... Cancer discovery 3 (6), 658-673, 2013	714	2013
Biomarkers predicting clinical outcome of epidermal growth factor receptor–targeted therapy in metastatic colorectal cancer S Siena, A Sartore-Bianchi, F Di Nicolantonio, J Balfour, A Bardelli Journal of the National Cancer Institute 101 (19), 1308-1324, 2009	712	2009
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth G Germano, S Lamba, G Rospo, L Barault, A Magrì, F Maione, M Russo, ... Nature 552 (7683), 116-120, 2017	616	2017
Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution S Misale, F Di Nicolantonio, A Sartore-Bianchi, S Siena, A Bardelli Cancer discovery 4 (11), 1269-1280, 2014	521	2014
Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer M Russo, G Siravegna, LS Blaszkowsky, G Corti, G Crisafulli, ... Cancer discovery 6 (2), 147-153, 2016	422	2016
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus F Di Nicolantonio, S Arena, J Tabernero, S Grosso, F Molinari, ... The Journal of clinical investigation 120 (8), 2858-2866, 2010	405	2010
Adaptive mutability of colorectal cancers in response to targeted therapies M Russo, G Crisafulli, A Sogari, NM Reilly, S Arena, S Lamba, A Bartolini, ... Science 366 (6472), 1473-1480, 2019	371	2019
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3 C Sun, S Hobor, A Bertotti, D Zecchin, S Huang, F Galimi, F Cottino, ... Cell reports 7 (1), 86-93, 2014	358	2014
EGFR Blockade Reverts Resistance to KRAS^G12C Inhibition in Colorectal Cancer V Amodio, R Yaeger, P Arcella, C Cancelliere, S Lamba, A Lorenzato, ... Cancer discovery 10 (8), 1129-1139, 2020	343	2020

Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.

Makaleler 1–20

Yıllık alıntı sayısı

Mükerrer alıntılar

Birleştirilmiş alıntılar

Katkıda bulunan yazar ekleKatkıda bulunan yazarlar

Takip et

Alıntı yapanlar

Katkıda bulunan yazarlar